Stevanato Group (STVN) to Release Quarterly Earnings on Tuesday

Stevanato Group (NYSE:STVN) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of €0.13 ($0.14) per share for the quarter. Stevanato Group has set its FY 2024 guidance at 0.520-0.540 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Stevanato Group (NYSE:STVN) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The business had revenue of €259.60 million during the quarter, compared to analyst estimates of €254.92 million. Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period last year, the business earned $0.15 EPS. On average, analysts expect Stevanato Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Stevanato Group Stock Performance

STVN opened at €19.59 ($21.29) on Monday. The stock’s 50 day moving average price is €19.57 and its two-hundred day moving average price is €20.45. The company has a quick ratio of 1.13, a current ratio of 1.74 and a debt-to-equity ratio of 0.19. Stevanato Group has a 12-month low of €16.56 ($18.00) and a 12-month high of €34.73 ($37.75).

Analyst Ratings Changes

A number of analysts have issued reports on the company. Citigroup lowered their target price on Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley lowered their target price on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.